HER-2 ADC
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients (NCT05912816) | RenJi Hospital | 2023-06-10 |
Track HER-2 ADC automatically
Every clearance here is in the API, with alerts when new ones post.